Insights · Grow

Marketing a weight loss practice after the compounding shift

Mohammed Ismail · 2026-10-03

In short: With the GLP-1 shortages over and regulators watching claims closely, weight loss practices can no longer win on price or bold promises. The practices that grow now compete on clinical care, clear wording, fast booking and strong follow-up past month three.

For a few years, many weight loss practices grew on one message: access to GLP-1 medication at a lower price. That message has a much shorter shelf life now. Here is what changed and how to market well in the new market.

General information only, not legal or medical advice. Your counsel should review claims for your specific programs.

What changed

  • The shortages ended. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025. That removed the main basis for large-scale compounding.
  • Claims came under scrutiny. Regulators sent dozens of warning letters to telehealth companies, mostly for suggesting compounded products were equivalent to FDA-approved drugs.
  • Large platforms moved in. Big telehealth brands built partnerships around approved drugs and cash-pay access, which made price a hard place for small practices to compete.
  • Weaker operators left. Practices without strong clinical operations, compliant tech and clear oversight scaled back or closed.

Words to stop using

Avoid Why
"Same as Ozempic" or "same as Wegovy" Suggests a compounded product equals an approved drug
"Generic semaglutide" There is no approved generic in that sense
"FDA-approved" about compounded medication Compounded drugs are not FDA-approved
"Lose 30 pounds guaranteed" Outcome guarantees invite liability and ad rejections
"Clinically proven" without context Needs substantiation for your specific program

Review ads, landing pages, emails and social posts together. Platforms and regulators look at all of it.

Compete on care, not on the molecule

Patients can buy medication from many places. What they can't buy everywhere is a program that works for them. Market what your practice actually does:

  • The clinician. Who evaluates, who follows up, how often.
  • The plan. Nutrition, activity, labs, side-effect management, what happens at each stage.
  • The support. How fast questions get answered, what happens if progress stalls.
  • The outcome you measure. Not a promise, but how you track progress with the patient.

Fix the flow before you buy traffic

Ad costs in this category are high. Before increasing spend, check the steps after the click:

  1. Booking. Can someone book a consult on a phone in under two minutes?
  2. Speed to lead. Does every inquiry get a helpful reply within minutes?
  3. Intake. Is it online and done before the visit?
  4. Show rate. How many booked consults actually happen?

A practice with a slow, leaky flow pays more for every patient, no matter how good the ads are.

Retention is where revenue is won

In cash-pay weight loss programs, the first months are often the hardest. Side effects, slow early progress and life getting busy all lead to drop-off. Plan for it:

  • Scheduled check-ins in the first 12 weeks, reviewed by your clinical team.
  • Refill and lab reminders that run automatically.
  • Progress moments the patient can see, not just the scale.
  • A save path when someone wants to pause, before they cancel.

Track month-3 retention every month. It tells you more about the health of the business than any ad dashboard.

Certification and ad platforms

If you prescribe online and advertise, expect to need LegitScript certification for Google and Meta, plus each platform's own checks. See LegitScript certification for telehealth. Meta also limits conversion tracking for health advertisers, so plan campaigns around top-of-funnel goals and in-platform lead forms.

Where to start

Start with the numbers that matter: cost per booked visit, show rate and month-3 retention. If you don't have them, the free Readiness Score shows where the biggest gaps likely are in about three minutes.

Key takeaways

  • Never imply a compounded drug equals an approved one
  • Sell the program and the care, not only the medication
  • Retention after month three is where revenue is won or lost
  • Certification and claims review come before ad spend
  • Measure cost per booked visit and month-3 retention, not clicks
Mohammed Ismail

Industrial Engineer. Founder of The Engineered Practice. Helps US cash-pay and telehealth practices map, fix, automate and grow their patient flow. About

General information only, not legal or medical advice.

Find out where your practice leaks patients.

15 questions, 3 minutes, a score for every stage of your patient flow. No health data asked.